ARB Marketers May Be Tense After AHRQ Comparative Effectiveness Report
Executive Summary
A comparative effectiveness review from the Agency for Healthcare Research and Quality comparing ACE inhibitors and ARBs may create challenges for brand manufacturers in formulary negotiations